| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
BioTechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
To whom requests for reprints should be addressed at 1 Eli Lilly and Company, BioTDR, DC 0444, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: saha{at}lilly.com
The effects of anesthetic agents, commonly used in animal models, on blood glucose levels in fed and fasted rats were investigated. In fed Sprague-Dawley rats, ketamine (100 mg/kg)/xylazine (10 mg/kg) (KX) produced acute hyperglycemia (blood glucose 178.4 ± 8.0 mg/dl) within 20 min. The baseline blood glucose levels (104.8 ± 5.7 mg/dl) reached maximum levels (291.7 ± 23.8 mg/dl) at 120 min. Ketamine alone did not elevate glucose levels in fed rats. Isoflurane also produced acute hyperglycemia similar to KX. Administration of pentobarbital sodium did not produce hyperglycemia in fed rats. In contrast, none of these anesthetic agents produced hyperglycemia in fasted rats. The acute hyperglycemic effect of KX in fed rats was associated with decreased plasma levels of insulin, adrenocorticotropic hormone (ACTH), and corticosterone and increased levels of glucagon and growth hormone (GH). The acute hyperglycemic response to KX was dose-dependently inhibited by the specific 
2-adrenergic receptor antagonist yohimbine (1–4 mg/kg). KX-induced changes of glucoregulatory hormone levels such as insulin, GH, ACTH, and corticosterone were significantly altered by yohimbine, whereas the glucagon levels remained unaffected. In conclusion, the present study indicates that both KX and isoflurane produce acute hyperglycemia in fed rats. The effect of KX is mediated by modulation of the glucoregulatory hormones through stimulation of 2-adrenergic receptors. Pentobarbital sodium did not produce hyperglycemia in either fed or fasted rats. Based on these findings, it is suggested that caution needs to be taken when selecting anesthetic agents, and fed or fasted state of animals in studies of diabetic disease or other models where glucose and/or glucoregulatory hormone levels may influence outcome and thus interpretation. However, fed animals are of value when exploring the hyperglycemic response to anesthetic agents.
Key Words: acute hyperglycemia • hypoinsulinemia • ketamine/xylazine anesthesia • anesthetic agents • fed animals • fasted animals • isoflurane • pentobarbital sodium • glucoregulatory hormones
This article has been cited by other articles:
|
|
 |
|
  K. Kohzaki, A. J. Vingrys, and B. V. Bui Early Inner Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3595 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Assadian, A. Aliaga, R. F. Del Maestro, A. C. Evans, and B. J. Bedell FDG-PET imaging for the evaluation of antiglioma agents in a rat model Neuro-oncol, January 1, 2008; 10(3): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Zuurbier, P. J. M. Keijzers, A. Koeman, H. B. Van Wezel, and M. W. Hollmann Anesthesia's Effects on Plasma Glucose and Insulin and Cardiac Hexokinase at Similar Hemodynamics and Without Major Surgical Stress in Fed Rats Anesth. Analg., January 1, 2008; 106(1): 135 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Marsh, P. C. Powell, A. Agarwal, L. J. Dell'Italia, and J. C. Chatham Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H292 - H298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-H. Yao and B. L. Gregoire Nyomba Abnormal glucose homeostasis in adult female rat offspring after intrauterine ethanol exposure Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2007; 292(5): R1926 - R1933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Saha, J. Xia, S. K. Engle, Y.-F. Chen, W. Glaesner, and J. A. Jakubowski A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and Glucagon-Like Peptide-1 Analog J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
